Trial record 3 of 16 for:
lung cancer | Kitchener, Canada
Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer With Osimertinib Third-line Rechallenge (OCELOT)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04335292 |
|
Recruitment Status :
Recruiting
First Posted : April 6, 2020
Last Update Posted : June 23, 2022
|
Sponsor:
Mark Vincent
Collaborator:
AstraZeneca
Information provided by (Responsible Party):
Mark Vincent, Lawson Health Research Institute
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | June 1, 2024 |
| Estimated Study Completion Date : | June 1, 2024 |